Aeglea BioTherapeutics, Inc. (AGLE) Social Stream
Aeglea BioTherapeutics Inc (AGLE) Price Targets From Analysts
Use the tables below to see what analysts covering Aeglea BioTherapeutics Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
AGLE's average price target has moved down $3.86 over the prior 46 weeks.
AGLE reports an average of 148.51% for its upside potential over the past 50 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
AGLE Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 59 days, AGLE's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, Aeglea BioTherapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 284.66% of them.
- In the context of all US stocks, Aeglea BioTherapeutics Inc's average analyst price target is higher than 37.37% of them.
- To contextualize these metrics, consider that out of all US stocks, Aeglea BioTherapeutics Inc's number of analysts covering the stock is greater than 57.24% of them.
- In the context of Pharmaceutical Products stocks, Aeglea BioTherapeutics Inc's variance in analysts' estimates is lower than -39.9% of them.
In the Pharmaceutical Products industry, AFMD, AEZS, and ADXS are the three stocks most similar to Aeglea BioTherapeutics Inc regarding the price target and analyst recommendation information presented here.
Is AGLE a Buy, Hold or Sell? See the POWR Ratings now!